Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage oncology company completed $318M IPO in Jan 2026 — first biotech IPO of 2026 (Nasdaq: AKTS); Eli Lilly took $100M stake; developing alpha-emitting radiopharmaceutical AKY-1189 targeting Nectin-4 for bladder and other solid tumors.
Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.
Doximity (NYSE: DOCS), professional network for US physicians with 2M+ verified clinicians; telehealth, medical news, and career tools monetized via pharmaceutical digital marketing.
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinicians on the platform — representing the majority of practicing US physicians — Doximity has established itself as the dominant professional network for doctors, providing identity-verified peer connections, specialty-specific news feeds, medical journal access, and career management tools including a physician job board and CV builder. The verification layer distinguishes Doximity from general professional networks and makes it the standard reference for confirming physician credentials and contact information across the healthcare industry.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.